Huawei Watch D3 lands in UK & Europe with improved blood pressure tracking

Following its official reveal earlier this month, Huawei’s latest BP watch lands with ambulatory monitoring

Huawei’s latest blood pressure smartwatch, the Watch D3, is now officially available across the UK and Europe following its initial reveal at the company's Munich launch event earlier this month.

Retailing at £399.99 / €399.99, the Watch D3 brings European CE-MDR medical certification and continuous blood pressure monitoring in a significantly sleeker form factor than the previous-gen Watch D2. It's now much more akin to the Watch Fit 5 series that debuted earlier this year.

Unlike other consumer smartwatch solutions we've seen roll out in the last 12-18 months that estimate blood pressure using existing optical sensors, the Watch D3 features a physical micro-pump and a 25.5mm inflatable airbag cuff built directly into the wrist strap.

This enables on-demand, multi-scenario blood pressure readings—including Ambulatory Blood Pressure Monitoring (ABPM)—to schedule overnight background checks and track hypertension trends.

While housing the mechanical pumping hardware, Huawei has also reduced the D3's physical footprint to just 11.3mm thick and 40g, making it more comfortable for overnight wear and continuous sleep tracking.

Software tweaks back up the new hardware

It's not all about the hardware, though. New software additions include integrated Health Glance overviews that map blood pressure trends alongside sleep, SpO2, and HRV metrics.

Pre- and post-exercise blood pressure tracking can now also help users monitor cardiovascular recovery and spot potential hypertensive responses during workouts, while D3 also adds Pulse Wave Arrhythmia Analysis for atrial fibrillation alerts and a separate beat-by-beat ECG app.

We're currently putting the Watch D3 through its paces for our full review, so stay tuned for our final verdict. Just keep in mind that—as with all its hardware—Huawei hasn't released the D3 in the US because of ongoing trade restrictions and regulatory constraints.